Geneva, April 28 -- International Clinical Trials Registry received information related to the study (NCT07537985) titled 'Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment' on April 12.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-sen University
Condition:
Hepatocellulcar Carcinoma
Intervention:
Drug: Lenvatinib
Drug: Regorafenib
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: January 1, 2020
Target Sample Size: 200
Countries of Recruitment:
China
To know more, visit ht...